Drug Type ASO, Drug conjugates |
Synonyms- |
Target |
Action inhibitors, agonists |
Mechanism DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 1 | Preclinical | United States | 01 Jun 2020 | |
| Diabetes Mellitus, Type 2 | Preclinical | United States | 01 Jun 2020 |





